Following the expression of interest at the 2018 Conference, the British Sarcoma Group invite you to attend a study day on the 13th February 2019 on the subject of “Improving Sarcoma MDTs”. The aim of the event is to consider the recommendations of the MDT review produced by Cancer Research UK, share ideas, problems and good practice […]
Abstract submission deadline extended! The British Sarcoma Group invites and encourages you to submit an abstract for the BSG Conference 2019. Abstracts can be submitted for an oral talk or poster display. The deadline for submitting an abstract has been extended to midnight on Sunday 9th December 2018. Instructions for submitters: All abstract submissions need to be submitted […]
April 2018 BSG guide for sonographers and primary care. Please note this is a draft document for consultation. Click HERE to access the document.
XXXI course on Musculoskeletal Pathology is being held on 16-20 April 2018, Istituto Ortopedico Rizzoli, Bologna, Italy. For further information please CLICK HERE.
BSG guide for sonographers and primary care. Please note this is a draft document for consultation. Click here to read the document.
The BSG programme is now available to view. Further updates may be made. Please click HERE for the BSG 2 day programme, 27.02.18 & Wednesday, 28.02.18. The National Sarcoma Forum is being held on the afternoon of Tuesday, 27.02.18. Please click HERE for the NSF programme, 27.02.18. We hope to see you in February for […]
We’re delighted to announce that registration for the first joint British Sarcoma & Irish Sarcoma Group conference is now open! You can register your place by clicking HERE The conference takes place across two days – Tuesday 27th & Wednesday 28th February 2018. There are a number of different ticket options available and all rates […]
Thank you to everyone who has submitted an abstract for 2018 conference. We’ve received a record number of papers and all notifications have been sent for successful oral and poster presentations. Any queries, please contact: firstname.lastname@example.org
Following on from the publication of exciting data from a phase 2 trial last year, NICE has now approved use of olaratumab in combination with doxorubicin for advanced soft tissue sarcoma (STS) in the first-line setting. Doxorubicin has been the backbone of first line chemotherapy for STS for over 30 years and the early data […]